# Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

> **NCT00880282** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 39 (actual)

## Conditions studied

- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** cixutumumab
- **DRUG:** temsirolimus
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00880282
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2012-10
- **Final completion:** —
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2014-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00880282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00880282, "Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00880282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*